Cara Therapeutics, Inc. (CARA) Given “Buy” Rating at Stifel Nicolaus
Cara Therapeutics, Inc. (NASDAQ:CARA)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a note issued to investors on Friday.
CARA has been the subject of several other reports. Raymond James Financial, Inc. reiterated a “market perform” rating and issued a $30.00 target price on shares of Cara Therapeutics in a report on Friday, April 28th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 target price on shares of Cara Therapeutics in a report on Friday, March 3rd. HC Wainwright upped their target price on Cara Therapeutics from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 28th. Zacks Investment Research cut Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 14th. Finally, Vetr upgraded Cara Therapeutics from a “hold” rating to a “buy” rating and set a $18.44 target price for the company in a report on Wednesday, April 5th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $26.30.
Shares of Cara Therapeutics (NASDAQ:CARA) opened at 22.65 on Friday. The company has a 50-day moving average price of $16.70 and a 200-day moving average price of $14.92. Cara Therapeutics has a 52 week low of $4.35 and a 52 week high of $23.55. The stock’s market cap is $736.28 million. Cara Therapeutics also was the target of unusually large options trading on Friday. Stock investors acquired 395 put options on the stock. This represents an increase of 150% compared to the typical volume of 158 put options.
Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by $0.08. The business had revenue of $0.91 million during the quarter, compared to analyst estimates of $0.11 million. During the same period last year, the company earned ($0.39) EPS. The company’s revenue for the quarter was up 12900.0% on a year-over-year basis. Equities analysts anticipate that Cara Therapeutics will post ($2.37) EPS for the current year.
In related news, major shareholder Ventures Vi Lp Rho acquired 500,000 shares of the firm’s stock in a transaction that occurred on Friday, March 31st. The stock was purchased at an average cost of $18.19 per share, for a total transaction of $9,095,000.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.
Large investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its stake in shares of Cara Therapeutics by 127.2% in the third quarter. Wells Fargo & Company MN now owns 12,007 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 6,722 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Cara Therapeutics during the first quarter worth $112,000. Private Advisor Group LLC bought a new stake in shares of Cara Therapeutics during the fourth quarter worth $117,000. Quantbot Technologies LP bought a new stake in shares of Cara Therapeutics during the first quarter worth $124,000. Finally, Flinton Capital Management LLC bought a new stake in shares of Cara Therapeutics during the fourth quarter worth $139,000. Hedge funds and other institutional investors own 52.91% of the company’s stock.
About Cara Therapeutics
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.